Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Capital Expenditures (2020 - 2025)

PROCEPT BioRobotics has reported Capital Expenditures over the past 6 years, most recently at $255000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $255000.0 for Q4 2025, down 78.28% from a year ago — trailing twelve months through Dec 2025 was $969000.0 (down 78.02% YoY), and the annual figure for FY2025 was $969000.0, down 78.02%.
  • Capital Expenditures for Q4 2025 was $255000.0 at PROCEPT BioRobotics, up from -$3.9 million in the prior quarter.
  • Over the last five years, Capital Expenditures for PRCT hit a ceiling of $8.4 million in Q2 2023 and a floor of -$14.6 million in Q4 2023.
  • Median Capital Expenditures over the past 5 years was $323500.0 (2021), compared with a mean of $524300.0.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 8017.81% in 2023 and later crashed 1695.12% in 2025.
  • PROCEPT BioRobotics' Capital Expenditures stood at $392000.0 in 2021, then skyrocketed by 525.77% to $2.5 million in 2022, then plummeted by 696.33% to -$14.6 million in 2023, then soared by 108.03% to $1.2 million in 2024, then tumbled by 78.28% to $255000.0 in 2025.
  • The last three reported values for Capital Expenditures were $255000.0 (Q4 2025), -$3.9 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.